Open AccessMesenchymal stem cells derived from human iPS cells via mesoderm and neuroepithelium have different features and therapeutic potentials
Author(s) -
S. Eto,
Mizuki Goto,
Minami Soga,
Yoshiaki Kaneko,
Yusuke Uehara,
Hiroshi Mizuta,
Takumi Era
Publication year - 2018
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0200790
Subject(s) - mesenchymal stem cell , induced pluripotent stem cell , mesoderm , regenerative medicine , neuroepithelial cell , microbiology and biotechnology , stem cell , biology , clinical uses of mesenchymal stem cells , cellular differentiation , stem cell transplantation for articular cartilage repair , adult stem cell , multipotent stem cell , endothelial stem cell , embryonic stem cell , in vitro , neural stem cell , genetics , progenitor cell , gene
Mesenchymal stem cells (MSCs) isolated from adult human tissues are capable of proliferating in vitro and maintaining their multipotency, making them attractive cell sources for regenerative medicine. However, the availability and capability of self-renewal under current preparation regimes are limited. Induced pluripotent stem cells (iPSCs) now offer an alternative, similar cell source to MSCs. Herein, we established new methods for differentiating hiPSCs into MSCs via mesoderm-like and neuroepithelium-like cells. Both derived MSC populations exhibited self-renewal and multipotency, as well as therapeutic potential in mouse models of skin wounds, pressure ulcers, and osteoarthritis. Interestingly, the therapeutic effects differ between the two types of MSCs in the disease models, suggesting that the therapeutic effect depends on the cell origin. Our results provide valuable basic insights for the clinical application of such cells.